NDATOPICALAEROSOL, FOAM
Approved
Jul 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
18
Data completeness
7/8 — Comprehensive
FINACEA (azelaic acid) by Leo Pharma is mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown. Approved for papulopustular rosacea, acne vulgaris, rosacea. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FINACEA (azelaic acid) is a topical foam treatment approved for papulopustular rosacea, acne vulgaris, and related dermatologic conditions. The mechanism of action remains incompletely understood, though the drug interferes with pathogenic events in rosacea through unknown pathways. It is indicated for multiple skin manifestations including erythema, post-inflammatory hyperpigmentation, seborrheic dermatitis, and perioral dermatitis.
$2MPart D
LOE Approaching2.8 years to LOELoss of exclusivity approaching in 2.9 years signals transition from brand protection to generic transition management, with modest team scale typical of topical dermatology portfolios.
Mechanism of Action
mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
Indications (3)
Worked on FINACEA at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.